Monitor for any Form 4 filings or 13D amendments indicating warrant exercise and subsequent selling by stockholders. The overhang from potential resale could pressure the stock in the near term, but the actual impact depends on the pace of exercise and market conditions.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $3.87entry
- T+1 · 5mo ago +5.17%α +4.39% · $4.07
- T+5 · 4mo ago +22.22%α +20.83% · $4.73
- T+20 · 4mo ago −3.62%α −3.34% · $3.73
- T+60 · 8w ago +25.58%α +21.20% · $4.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M to 60M shares (post reverse-split), enabling the exercise of outstanding warrants held by selling stockholders. The filing also confirms the effectiveness of a previously filed S-3 registration statement covering up to 10.875M post-split shares for resale. This is a procedural step in the capital restructuring announced in March 2026, with no new financial disclosures or immediate fundraising.
Key Facts
- Authorized common stock increased from 18,750,000 to 60,000,000 shares (post-1-for-8 reverse split effective May 29, 2026).
- Shareholders approved the amendment at the June 25, 2026 Annual Meeting.
- Registration statement on Form S-3 (effective May 8, 2026) registers up to 10,875,000 post-split shares for resale by selling stockholders.
- Warrants (pre-funded and common) became exercisable upon the effectiveness of the authorized share increase on June 26, 2026.
- No new offering or additional capital raise; all shares registered are already issued or issuable upon existing warrants.
Financial Impact
Potential dilution of up to 10.875 million shares (post-split) upon warrant exercise, with corresponding cash proceeds to the company from warrant exercises (pre-funded warrants at $0.0001/share, common warrants at $9.60/share post-split). No immediate financial impact as no shares were sold in this filing.
Risk Factors
- Dilution from exercise of common warrants (5.4375M post-split shares at $9.60 exercise price) and pre-funded warrants (1.09375M shares).
- Selling pressure from stockholders registered for resale on the S-3.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000021 |
| Document: scyx-ex5_1.htm | 0001178253-26-000021 |
| Document: scyx-ex3_1.htm | 0001178253-26-000021 |
| Document: 0001178253-26-000021-index-headers.html | 0001178253-26-000021 |
| Document: 0001178253-26-000021-index.html | 0001178253-26-000021 |
| Document: 0001178253-26-000021.txt | 0001178253-26-000021 |
Track record
15 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $2.91 Now $2.91 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Viewing Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers